Bellerophon Provides Clinical Program Update and Reports

Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 ...

Related Keywords

New Jersey ,United States ,Peter Fernandes ,Baylor Biosciences ,Brian Ritchie ,Baylor Bioscience ,Exchange Commission ,Jersey Technology Business Tax Certificate Transfer Program ,Clinical Program ,Nasdaq ,Baylor Biosciences Inc ,Bellerophon Therapeutics Inc ,Last Patient Completed Blinded Treatment ,Pivotal Top Line Data Expected ,Chief Executive ,Program Highlights ,Interstitial Lung Disease ,Vigorous Physical Activity ,Quarter Ended March ,Financial Results ,Private Securities Litigation Reform Act ,Annual Report ,Sci Advisors ,Operations And Comprehensive Income ,Nasdaq Blph ,Bellerophon Therapeutics ,Nc ,